toggle

Autolus Therapeutics plc

Latest Autolus Therapeutics plc News and Updates

Miscellaneous

T-Cell Pipeline Is a Key Growth Driver for Autolus Therapeutics

The 12-month consensus analyst recommendation for Autolus Therapeutics (AUTL) on September 25 is a “strong buy.”

ABOUT Market Realist
About Us
Privacy Policy
Terms of Use
DMCA

CONNECT with Market Realist

© Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.